AMPH vs REGN · P/E 12, rev $732.0M vs P/E 14, rev $14.34B
Amphastar P (AMPH) versus Regeneron Pharmaceuticals Inc (REGN) — a side-by-side from cached financials, not a winner call.
Amphastar P (AMPH) is a drug manufacturers - specialty & generic company listed on NASDAQ.
Regeneron Pharmaceuticals Inc (REGN) is a biotechnology company listed on US.
Latest reported AMPH revenue for 2024-12-31 was $732.0M. Net income was $159.5M. Revenue was up 13.6% from 2023-12-31 to 2024-12-31. AMPH currently screens at market cap $880.1M and trailing P/E 12.0.
Latest reported REGN revenue for 2025-12-31 was $14.34B. Net income was $4.50B. Revenue was up 1.0% from 2024-12-31 to 2025-12-31. REGN currently screens at market cap $59.10B and trailing P/E 13.9.
AMPH currently screens at market cap $880.1M and trailing P/E 12.0. REGN currently screens at market cap $59.10B and trailing P/E 13.9.
Not investment advice. Open the AMPH and REGN stock pages for the full models.
Not investment advice.